TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Chemomab Therapeutics ( (CMMB) ).
Chemomab Therapeutics announced its third quarter 2025 financial results and provided a corporate update, highlighting significant progress in its nebokitug Phase 3 trial for primary sclerosing cholangitis (PSC). The company received positive feedback from both the FDA and EMA, supporting a single Phase 3 registration trial with a composite endpoint, and presented favorable Phase 2 data at the AASLD 2025 conference. Chemomab is exploring multiple partnering options to support the Phase 3 program and expects its cash runway to last through the end of 2026.
The most recent analyst rating on (CMMB) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.
Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.
To see Spark’s full report on CMMB stock, click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet needs.
Average Trading Volume: 179,584
Technical Sentiment Signal: Sell
Current Market Cap: $13.97M
See more insights into CMMB stock on TipRanks’ Stock Analysis page.